Pralatrexate in Patients With Recurrent or Refractory Peripheral T-Cell Lymphomas: A Multicenter Retrospective Analysis

Scientific Reports - United Kingdom
doi 10.1038/s41598-019-56891-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pralatrexate for Refractory or Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma With Hemophagocytic Syndrome

Journal of the American Academy of Dermatology
Dermatology
2020English

A Single Center Phase II Study of Ixazomib in Patients With Relapsed or Refractory Cutaneous or Peripheral T-Cell Lymphomas

American Journal of Hematology
Hematology
2017English

Survival Benefit With Novel Agents in Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (Ptcl): The Columbia University Experience

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase 1 Study of Pralatrexate Plus Romidepsin Reveals Marked Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Recurrent Presence of the PLCG1 S345F Mutation in Nodal Peripheral T-Cell Lymphomas

Haematologica
Hematology
2014English

High-Dose Therapy With Autologous Stem Cell Transplantation in Patients With Peripheral T Cell Lymphomas

Bone Marrow Transplantation
TransplantationHematology
2001English

Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Cyclin D1 Expression in Peripheral T-Cell Lymphomas

Modern Pathology
Forensic MedicinePathology
2016English

The Aggressive Peripheral T-Cell Lymphomas: 2017

American Journal of Hematology
Hematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy